QSP Modeling for Inflammatory Bowel Disease (IBD) with Certara IQ™

Introducing Certara IQ, an AI enabled modeling platform for scaling and democratizing QSP modeling. Certara IQ offers a range of model libraries licensed separately, spanning numerous pharmacologies and therapeutic areas.

In this video, we are joined by Douglas Chung, Certara’s QSP modeler, who has led the development of the IBD clinical score predictor.

To start, let’s explore the impact of Certara’s QSP model for inflammatory bowel disease or IBD in today’s therapeutic landscape.

So, Doug, why is this model important right now for addressing the current challenges when we talk about IBD therapy development and how does it impact decision making?

So we aim to improve treatment outcomes by using modeling and simulation. We’re using the IBD QSP model. Because currently the treatment paradigm is that one size fits all, that we can simply repurpose existing autoimmune therapies and bring it into IBD. But it’s contextually very different. The biology is different, and the treatment response is quite different. So in order to improve outcomes, we predict clinical scores by using virtual populations, and we predict novel combination therapies, and also try and find prognostic biomarkers that are indicative of patient response. So what this does is it helps the drug development team decide on the right target and the right approach for the right patient.

Thanks, Doug. I believe that context provides the strong foundation. I’d like to now dig in deeper into how this innovative model improves patient care. So how does the IVD model advance our ability to personalize treatment strategies for Crohn’s disease and ulcerative colitis. And what makes this especially relevant today for modern teams that are aiming for more targeted and effective outcomes?

Sure. One of the main challenges with personalizing treatment and IBD is to understand who are the non responders.

So what we can do with the modeling is to identify the exact mechanisms and actually provide a biological rationale for a patient’s non response to a particular treatment regimen.

So by better understanding the patient profile and also, understanding how the treatment impacts the patient’s disease progression, we can try novel combination therapies, which further personalizes the approach. And the way we do this is by inputting the observed data from different monotherapy trials and then predicting the response and or remission following a combination therapy. So the idea is that this model gets better over time. We stress test this QSP model with new targets, new therapies, new patient subtypes, and we iteratively train and test the model. It gets better over time.

Thank you, Doug, for talking to us about Certara IQ’s inflammatory bowel disease QSP platform model.

Sure. Thanks for your time.

With intuitive and scalable QSP model building, Certara IQ helps transform your drug development. To learn more about the IBD and other platform models, visit our website.